行情

SRNE

SRNE

Sorrento Thera
NASDAQ

实时行情|Nasdaq Last Sale

1.520
+0.070
+4.83%
交易中 14:32 11/19 EST
开盘
1.460
昨收
1.450
最高
1.580
最低
1.460
成交量
55.25万
成交额
--
52周最高
6.50
52周最低
1.390
市值
1.99亿
市盈率(TTM)
-0.7036
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SRNE 新闻

  •  Sorrento CEO to Present at Upcoming Investor Conferences
  • GlobeNewswire.11/12 12:05
  • Sorrentto Therapeutics Inc (SRNE): Are Hedge Funds Right About This Stock?
  • Insider Monkey.11/07 22:05
  • Sorrento to Present New Data on Advanced Immunotherapies at ASH 2019 and Other Conferences
  • Benzinga.11/07 08:27
  • Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
  • GlobeNewswire.11/07 00:37

更多

所属板块

生物技术和医学研究
+2.18%
制药与医学研究
+0.76%

热门股票

名称
价格
涨跌幅

SRNE 简况

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
展开

Webull提供Sorrento Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。